PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.
Adam A KrayaKara N MaxwellMonika A EivaBradley S WubbenhorstJohn PlutaMichael FeldmanAnupma NayakDaniel J PowellSusan M DomchekRobert A AndersKatherine L NathansonPublished in: JCO precision oncology (2022)
-associated ovarian cancers may inform considerations around how to optimally deploy immune checkpoint inhibitors in the clinic.